Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

NCT04833114 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

306

Enrollment

OTHER

Sponsor class

Conditions

Relapsed Diffuse Large B-cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma

Interventions

DRUG: Polatuzumab Vedotin
DRUG: Mabthera
DRUG: Ifosfamide
DRUG: Carboplatin
DRUG: Etoposide

Sponsor

GWT-TUD GmbH

Collaborators

[object Object]